Vismodegib

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1011 publications

Extensive Flexural Basal Cell Carcinomas Revealing Gorlin-Goltz Syndrome With Marked Histopathologic Diversity: A Case Report.

Extensive Flexural Basal Cell Carcinomas Revealing Gorlin-Goltz Syndrome With Marked Histopathologic Diversity: A Case Report.

Journal: Cureus

Published: May 18, 2026

Advanced Basal Cell Carcinoma in a Geriatric Patient: A Case Report and Ethical Considerations.

Advanced Basal Cell Carcinoma in a Geriatric Patient: A Case Report and Ethical Considerations.

Journal: Cureus

Published: May 04, 2026

Structure Merging Approach Leads to New Dual Potent and Selective USP25/USP28 Inhibitors.

Structure Merging Approach Leads to New Dual Potent and Selective USP25/USP28 Inhibitors.

Journal: Journal of medicinal chemistry

Published: April 22, 2026

Impact of Gamma Irradiation and Ethylene Oxide Sterilisation on the Stability of Crystalline and Amorphous Drug Solids.

Impact of Gamma Irradiation and Ethylene Oxide Sterilisation on the Stability of Crystalline and Amorphous Drug Solids.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Published: April 09, 2026

L-Carnitine in Dermatology: A Systematic Review of Therapeutic Potential and Biomarker Applications.

L-Carnitine in Dermatology: A Systematic Review of Therapeutic Potential and Biomarker Applications.

Journal: Journal of cutaneous medicine and surgery

Published: March 25, 2026

Acquired Kinky Hairs due to Hedgehog Pathway Inhibition From Vismodegib.

Acquired Kinky Hairs due to Hedgehog Pathway Inhibition From Vismodegib.

Journal: International journal of dermatology

Published: March 20, 2026

Clinical Prioritization of Adverse Events Associated With Hedgehog Pathway Inhibitors in Basal Cell Carcinoma Patients: Insights From the FDA Adverse Event Reporting (FAERS) System.

Clinical Prioritization of Adverse Events Associated With Hedgehog Pathway Inhibitors in Basal Cell Carcinoma Patients: Insights From the FDA Adverse Event Reporting (FAERS) System.

Journal: Journal of cutaneous medicine and surgery

Published: March 19, 2026

GLIS3 drives epithelial-mesenchymal transition and cancer stem-like traits in stomach adenocarcinoma via TGFBR3-Hedgehog signaling.

GLIS3 drives epithelial-mesenchymal transition and cancer stem-like traits in stomach adenocarcinoma via TGFBR3-Hedgehog signaling.

Journal: Frontiers in oncology

Published: March 09, 2026

Ag-Sn@MOFs heterostructure enables ultrasensitive voltammetric determination of vismodegib in serum and urine.

Ag-Sn@MOFs heterostructure enables ultrasensitive voltammetric determination of vismodegib in serum and urine.

Journal: RSC advances

Published: March 07, 2026

Locally Advanced Basal Cell Carcinoma With Orbital Invasion: Treatment With Neoadjuvant Hedgehog Pathway Inhibition and Palliative Enucleation.

Locally Advanced Basal Cell Carcinoma With Orbital Invasion: Treatment With Neoadjuvant Hedgehog Pathway Inhibition and Palliative Enucleation.

Journal: Cureus

Published: February 22, 2026

Novel green-emissive carbon dots as a dual-purpose fluorometric tool for sensitive vismodegib detection and pharmacokinetic analysis.

Novel green-emissive carbon dots as a dual-purpose fluorometric tool for sensitive vismodegib detection and pharmacokinetic analysis.

Journal: Analytical methods : advancing methods and applications

Published: February 17, 2026

Impact of Reporter Type on Signal Detection of Cancer Therapy-Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System.

Impact of Reporter Type on Signal Detection of Cancer Therapy-Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: February 16, 2026

Showing 1-12 of 1,011

Last Updated: 06/30/2026